Citius Oncology, Inc. CTOR Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s shares (diluted)?
- Citius Oncology, Inc. (CTOR) reported shares (diluted) of 100M in Q1 2026.
- How has Citius Oncology, Inc.'s shares (diluted) changed year-over-year?
- Citius Oncology, Inc.'s shares (diluted) increased by 39.8% year-over-year, from 71.6M to 100M.
- What is the long-term trend for Citius Oncology, Inc.'s shares (diluted)?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s shares (diluted) has grown at a 180.2% compound annual growth rate (CAGR), from 36.7M to 287.9M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.